Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade

Fig. 2

Rigosertib increases the frequency of dendritic cells in tumors and tumor-draining lymph nodes (TDLN). YUMM3.3 tumors and TDLN were collected 17 days post-treatment. a Total number and density of CD45+ leukocytes in tumors were obtained by flow cytometry. b Gating strategy for dendritic cells in tumors and TDLN. c-e Frequency and mean fluorescent intensity (MFI) of dendritic cell subsets and their correlation with tumor burden. Pooled data obtained from at least two different experiments (n = 5 ~ 10) are shown

Back to article page

Molecular Cancer

ISSN: 1476-4598